Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Vascular Pharmacology
  4. Fast Track Articles
  5. Fast Track Article
image of The Link between Arterial Atherosclerotic and Venous Thromboembolic Disease

Abstract

Traditionally, arterial atherosclerotic (AA) and venous thromboembolic (VTE) diseases have been separated into two independent entities. However, a body of evidence suggests the link between arterial and venous disease. In this narrative review, the relationship between these two vascular diseases is discussed. Different risk factors are common in both diseases, such as dyslipidaemia, metabolic syndrome, and thrombophilia. Etiopathogenetic mechanisms of both diseases are similar. Inflammation, as a basic pathogenetic mechanism of atherosclerotic disease, is also involved in the pathogenesis of VTE. Inflammation as a response to vessel wall injury promotes coagulation and inhibits endogenic fibrinolytic activity, which results in thromboembolic events in the arterial as well as in the venous system. A relationship has also been observed between preclinical or clinical atherosclerotic disease and VTE. These findings indicate that atherosclerosis may induce VTE or that common risk factors simultaneously stimulate the development of both diseases. The relationship between arterial and venous disease is also supported by the efficacy of some drugs (antiplatelets, anticoagulants, statins) in the prevention of both diseases.

In conclusion, arterial and venous diseases share similar pathophysiological mechanisms, often driven by common risk factors. This overlap suggests that a unified approach to prevention and treatment may be beneficial for both conditions, potentially improving patient outcomes by addressing the underlying shared pathways.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611345232250212042958
2025-02-13
2025-05-05

  • From This Site

    /content/journals/cvp/10.2174/0115701611345232250212042958
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Prandoni P. Links between arterial and venous disease. J. Intern. Med. 2007 262 3 341 350 10.1111/j.1365‑2796.2007.01815.x 17697155
    [Google Scholar]
  2. Prandoni P. Bilora F. Marchiori A. Bernardi E. Petrobelli F. Lensing A.W.A. Prins M.H. Girolami A. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 2003 348 15 1435 1441 10.1056/NEJMoa022157 12686699
    [Google Scholar]
  3. Nogueira J.F.L. Teixeira-Viana F.C. Barboza-Silva B.L. Mendes-Pinto D. Rodrigues-Machado M.G. Advanced Levels of Chronic Venous Insufficiency are Related to an Increased in Arterial Stiffness. Ann. Vasc. Surg. 2023 96 365 373 10.1016/j.avsg.2023.03.013 37003361
    [Google Scholar]
  4. Auzky O. Lanska V. Pitha J. Roztocil K. Association between symptoms of chronic venous disease in the lower extremities and cardiovascular risk factors in middle-aged women. Int. Angiol. 2011 30 4 335 341 21747352
    [Google Scholar]
  5. Angchaisuksiri P. Arterial and venous thrombosis: shared risk factors and pathophysiology. J Hematol Transfus Med 2019 29 355 362
    [Google Scholar]
  6. Croce K. Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol. 2007 14 1 55 61 10.1097/00062752‑200701000‑00011 17133101
    [Google Scholar]
  7. Jezovnik M.K. Fareed J. Poredos P. Patients With a History of Idiopathic Deep Venous Thrombosis Have Long-Term Increased Levels of Inflammatory Markers and Markers of Endothelial Damage. Clin. Appl. Thromb. Hemost. 2017 23 2 124 131 10.1177/1076029616670259 27663463
    [Google Scholar]
  8. Kong P. Cui Z.Y. Huang X.F. Zhang D.D. Guo R.J. Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct. Target. Ther. 2022 7 1 131 10.1038/s41392‑022‑00955‑7 35459215
    [Google Scholar]
  9. Poredos P. Jezovnik M.K. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels 2011 26 6 596 602 10.1007/s00380‑010‑0111‑3 21267581
    [Google Scholar]
  10. Del Conde I. López J.A. Classification of venous thromboembolism (VTE). J. Thromb. Haemost. 2005 3 11 2573 2575 10.1111/j.1538‑7836.2005.01660.x 16241956
    [Google Scholar]
  11. Esmon C.T. Inflammation and thrombosis. J. Thromb. Haemost. 2003 1 7 1343 1348 10.1046/j.1538‑7836.2003.00261.x 12871267
    [Google Scholar]
  12. Burzynski L.C. Humphry M. Pyrillou K. Wiggins K.A. Chan J.N.E. Figg N. Kitt L.L. Summers C. Tatham K.C. Martin P.B. Bennett M.R. Clarke M.C.H. The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin. Immunity 2019 50 4 1033 1042.e6 10.1016/j.immuni.2019.03.003 30926232
    [Google Scholar]
  13. Collen D. Hoylaerts M.F. Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma. J. Am. Coll. Cardiol. 2005 45 9 1472 1473 10.1016/j.jacc.2005.02.029 15862421
    [Google Scholar]
  14. Poredoš P. Interrelationship between venous and arterial thrombosis. Int. Angiol. 2017 36 4 295 298 10.23736/S0392‑9590.17.03820‑2 28263045
    [Google Scholar]
  15. Mili FD Family history of myocardial infarction is a risk factor for venous thromboembolism among whites but not among blacks. Clin Appl Thromb Hemost. 2013 19 4 410 417
    [Google Scholar]
  16. Lassila R. Role and management of coagulation disorders in peripheral arterial disease. Scand J Surg. 2012 101 2 94 99 10.1177/145749691210100204
    [Google Scholar]
  17. Keller K. Prochaska J.H. Coldewey M. Göbel S. Schmitt V.H. Hahad O. Ullmann A. Nagler M. Lamparter H. Espinola-Klein C. Münzel T. Wild P.S. Atherosclerosis and Its Impact on the Outcomes of Patients with Deep Venous Thrombosis. Life (Basel) 2022 12 5 734 10.3390/life12050734 35629401
    [Google Scholar]
  18. Falk E Thuesen L Pathology of coronary microembolisation and no reflow. Heart 2003 89 9 983 985 10.1136/heart.89.9.983
    [Google Scholar]
  19. Libertiny G. Hands L. Deep venous thrombosis in peripheral vascular disease. Br. J. Surg. 1999 86 7 907 910 10.1046/j.1365‑2168.1999.01129.x 10417563
    [Google Scholar]
  20. Sykora D. Firth C. Girardo M. Bhatt S. Tseng A. Chamberlain A. Liedl D. Wennberg P. Shamoun F.E. Peripheral artery disease and the risk of venous thromboembolism. Vasa 2022 51 6 365 371 10.1024/0301‑1526/a001029 36134738
    [Google Scholar]
  21. Tripodi A. Branchi A. Chantarangkul V. Clerici M. Merati G. Artoni A. Mannucci P.M. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J. Thromb. Thrombolysis 2011 31 2 165 172 10.1007/s11239‑010‑0506‑0 20640482
    [Google Scholar]
  22. Previtali E. Bucciarelli P. Passamonti S.M. Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011 9 2 120 138 21084000
    [Google Scholar]
  23. Mari D. Ogliari G. Castaldi D. Vitale G. Bollini E.M. Lio D. Hemostasis and ageing. Immun. Ageing 2008 5 1 12 10.1186/1742‑4933‑5‑12 18947391
    [Google Scholar]
  24. Kannel W.B. Wolf P.A. Castelli W.P. D’Agostino R.B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987 258 9 1183 1186 10.1001/jama.1987.03400090067035 3626001
    [Google Scholar]
  25. Gleerup G. Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995 46 8 715 718 10.1177/000331979504600810 7639418
    [Google Scholar]
  26. Franchini M. Targher G. Montagnana M. Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb. Res. 2008 122 6 727 735 10.1016/j.thromres.2007.09.010 17996282
    [Google Scholar]
  27. Stubblefield W.B. Alves N.J. Rondina M.T. Kline J.A. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism. PLoS One 2016 11 2 e0148747 10.1371/journal.pone.0148747 26866684
    [Google Scholar]
  28. Morel S. Kwak B. Rohner-Jeanrenaud F. Steffens S. Molica F. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb. Haemost. 2015 113 3 553 566 10.1160/TH14‑06‑0513 25338625
    [Google Scholar]
  29. Ageno W. Becattini C. Brighton T. Selby R. Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008 117 1 93 102 10.1161/CIRCULATIONAHA.107.709204 18086925
    [Google Scholar]
  30. Cheng Y.J. Liu Z.H. Yao F.J. Zeng W.T. Zheng D.D. Dong Y.G. Wu S.H. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013 10 9 e1001515 10.1371/journal.pmed.1001515 24068896
    [Google Scholar]
  31. Pomp E.R. Rosendaal F.R. Doggen C.J.M. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am. J. Hematol. 2008 83 2 97 102 10.1002/ajh.21059 17726684
    [Google Scholar]
  32. Messner B. Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2014 34 3 509 515 10.1161/ATVBAHA.113.300156 24554606
    [Google Scholar]
  33. Poredoš P. Mukherjee D. Blinc A. Statins and Venous Thromboembolic Disease – Where are we Now? Curr. Vasc. Pharmacol. 2024 22 4 297 300 10.2174/0115701611308323240229050237 38441024
    [Google Scholar]
  34. Morelli V.M. Lijfering W.M. Bos M.H.A. Rosendaal F.R. Cannegieter S.C. Lipid levels and risk of venous thrombosis: results from the MEGA-study. Eur. J. Epidemiol. 2017 32 8 669 681 10.1007/s10654‑017‑0251‑1 28540474
    [Google Scholar]
  35. Deguchi H. Pecheniuk N.M. Elias D.J. Averell P.M. Griffin J.H. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005 112 6 893 899 10.1161/CIRCULATIONAHA.104.521344 16087810
    [Google Scholar]
  36. Huang Y. Ge H. Wang X. Zhang X. Association Between Blood Lipid Levels and Lower Extremity Deep Venous Thrombosis: A Population-Based Cohort Study. Clin. Appl. Thromb. Hemost. 2022 28 10760296221121282 10.1177/10760296221121282 36189865
    [Google Scholar]
  37. Glynn R.J. Danielson E. Fonseca F.A.H. Genest J. Gotto A.M. Jr Kastelein J.J.P. Koenig W. Libby P. Lorenzatti A.J. MacFadyen J.G. Nordestgaard B.G. Shepherd J. Willerson J.T. Ridker P.M. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009 360 18 1851 1861 10.1056/NEJMoa0900241 19329822
    [Google Scholar]
  38. Poredos P. Jezovnik M.K. Dyslipidemia, statins, and venous thromboembolism. Semin. Thromb. Hemost. 2011 37 8 897 902 10.1055/s‑0031‑1297368 22198854
    [Google Scholar]
  39. Quist-Paulsen P. Naess I.A. Cannegieter S.C. Romundstad P.R. Christiansen S.C. Rosendaal F.R. Hammerstrøm J. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010 95 1 119 125 10.3324/haematol.2009.011866 19713225
    [Google Scholar]
  40. Petrauskiene V. Falk M. Waernbaum I. Norberg M. Eriksson J.W. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005 48 5 1017 1021 10.1007/s00125‑005‑1715‑5 15778859
    [Google Scholar]
  41. Nazarzadeh M. Bidel Z. Mohseni H. Canoy D. Pinho-Gomes A.C. Hassaine A. Dehghan A. Tregouet D.A. Smith N.L. Rahimi K. Blood pressure and risk of venous thromboembolism: a cohort analysis of 5.5 million UK adults and Mendelian randomization studies. Cardiovasc. Res. 2023 119 3 835 842 10.1093/cvr/cvac135 36031541
    [Google Scholar]
  42. Di Minno M.N.D. Ambrosino P. Ageno W. Rosendaal F. Di Minno G. Dentali F. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb. Res. 2015 135 5 923 932 10.1016/j.thromres.2015.03.010 25784135
    [Google Scholar]
  43. Arachchillage D.J. Mackillop L. Chandratheva A. Motawani J. MacCallum P. Laffan M. Thrombophilia testing: A British Society for Haematology guideline. Br. J. Haematol. 2022 198 3 443 458 10.1111/bjh.18239 35645034
    [Google Scholar]
  44. Kim R.J. Becker R.C. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am. Heart J. 2003 146 6 948 957 10.1016/S0002‑8703(03)00519‑2 14660985
    [Google Scholar]
  45. Hamedani A.G. Cole J.W. Mitchell B.D. Kittner S.J. Meta-analysis of factor V Leiden and ischemic stroke in young adults: the importance of case ascertainment. Stroke 2010 41 8 1599 1603 10.1161/STROKEAHA.110.581256 20616326
    [Google Scholar]
  46. Chiasakul T. De Jesus E. Tong J. Chen Y. Crowther M. Garcia D. Chai-Adisaksopha C. Messé S.R. Cuker A. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta‐Analysis. J. Am. Heart Assoc. 2019 8 19 e012877 10.1161/JAHA.119.012877 31549567
    [Google Scholar]
  47. Ken-Dror G. Cooper J.A. Humphries S.E. Drenos F. Ireland H.A. Free protein S level as a risk factor for coronary heart disease and stroke in a prospective cohort study of healthy United Kingdom men. Am. J. Epidemiol. 2011 174 8 958 968 10.1093/aje/kwr203 21911828
    [Google Scholar]
  48. Sørensen H.T. Horvath-Puho E. Pedersen L. Baron J.A. Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007 370 9601 1773 1779 10.1016/S0140‑6736(07)61745‑0 18037081
    [Google Scholar]
  49. Knight R. Walker V. Ip S. Cooper J.A. Bolton T. Keene S. Denholm R. Akbari A. Abbasizanjani H. Torabi F. Omigie E. Hollings S. North T.L. Toms R. Jiang X. Angelantonio E.D. Denaxas S. Thygesen J.H. Tomlinson C. Bray B. Smith C.J. Barber M. Khunti K. Davey Smith G. Chaturvedi N. Sudlow C. Whiteley W.N. Wood A.M. Sterne J.A.C. Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales. Circulation 2022 146 12 892 906 10.1161/CIRCULATIONAHA.122.060785 36121907
    [Google Scholar]
  50. Karakasis P. Nasoufidou A. Sagris M. Fragakis N. Tsioufis K. Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review. Life (Basel) 2024 14 5 545 10.3390/life14050545 38792566
    [Google Scholar]
  51. Semeraro N. Colucci M. The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects. Mediterr. J. Hematol. Infect. Dis. 2021 13 1 e2021045 10.4084/MJHID.2021.045 34276914
    [Google Scholar]
  52. Kyriakoulis K.G. Kollias A. Kyriakoulis I.G. Kyprianou I.A. Papachrysostomou C. Makaronis P. Kotronias R.A. Terentes-Printzios D. Toskas I. Mikhailidis D.P. Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. Curr. Vasc. Pharmacol. 2022 20 1 96 110 10.2174/1570161119666210824160332 34431465
    [Google Scholar]
  53. Li J. Li Y. Wang Z. Liu N. He L. Zhang H. Increased risk of new-onset diabetes in patients with COVID-19: a systematic review and meta-analysis. Front. Public Health 2023 11 1170156 10.3389/fpubh.2023.1170156 37304092
    [Google Scholar]
  54. Jung H.S. Choi J.W. Association between COVID-19 and incidence of cardiovascular disease and all-cause mortality among patients with diabetes. Front. Endocrinol. (Lausanne) 2023 14 1230176 10.3389/fendo.2023.1230176 37576978
    [Google Scholar]
  55. Calvisi S.L. Ramirez G.A. Scavini M. Da Prat V. Di Lucca G. Laurenzi A. Gallina G. Cavallo L. Borio G. Farolfi F. Pascali M. Castellani J. Lampasona V. D’Angelo A. Landoni G. Ciceri F. Querini P.R. Tresoldi M. Piemonti L. Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. Metabolism 2021 123 154845 10.1016/j.metabol.2021.154845 34364927
    [Google Scholar]
  56. Pantea Stoian A. Bica I.C. Salmen T. Al Mahmeed W. Al-Rasadi K. Al-Alawi K. Banach M. Banerjee Y. Ceriello A. Cesur M. Cosentino F. Firenze A. Galia M. Goh S.Y. Janez A. Kalra S. Kapoor N. Kempler P. Lessan N. Lotufo P. Mikhailidis D.P. Nibali L. Papanas N. Powell-Wiley T. Rizvi A.A. Sahebkar A. Santos R.D. Toth P.P. Viswanathan V. Rizzo M. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review. Diabetes Ther. 2024 15 1 33 60 10.1007/s13300‑023‑01465‑7 37751143
    [Google Scholar]
  57. Becattini C. Agnelli G. Prandoni P. Silingardi M. Salvi R. Taliani M.R. Poggio R. Imberti D. Ageno W. Pogliani E. Porro F. Casazza F. A prospective study on cardiovascular events after acute pulmonary embolism. Eur. Heart J. 2005 26 1 77 83 10.1093/eurheartj/ehi018 15615803
    [Google Scholar]
  58. Prandoni P. Ghirarduzzi A. Prins M.H. Pengo V. Davidson B.L. Sørensen H. Pesavento R. Iotti M. Casiglia E. Iliceto S. Pagnan A. Lensing A.W.A. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J. Thromb. Haemost. 2006 4 9 1891 1896 10.1111/j.1538‑7836.2006.02058.x 16961597
    [Google Scholar]
  59. Jezovnik M.K. Poredos P. Lusa L. Idiopathic venous thrombosis is associated with preclinical atherosclerosis. J. Atheroscler. Thromb. 2010 17 3 304 311 10.5551/jat.3079 20103975
    [Google Scholar]
  60. Jezovnik M.K. Poredos P. Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis. J. Atheroscler. Thromb. 2010 17 11 1190 1198 10.5551/jat.4960 20702975
    [Google Scholar]
  61. Jeraj L. Spirkoska A. Ježovnik M.K. Poredoš P. Deep vein thrombosis and properties of the arterial wall. Vasa 2018 47 3 197 202 10.1024/0301‑1526/a000695 29485363
    [Google Scholar]
  62. Poredos P. Jezovnik M. Enlargement of the diameter of the peripheral arteries in patients with idiopathic venous thrombosis. Ultraschall Med. 2011 33 7 E268 E274 10.1055/s‑0031‑1273471 21863540
    [Google Scholar]
  63. Hong C. Zhu F. Du D. Pilgram T. Sicard G. Bae K. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005 183 1 169 174 10.1016/j.atherosclerosis.2005.03.047 15939424
    [Google Scholar]
  64. Grady D. Wenger N.K. Herrington D. Khan S. Furberg C. Hunninghake D. Vittinghoff E. Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med. 2000 132 9 689 696 10.7326/0003‑4819‑132‑9‑200005020‑00002 10787361
    [Google Scholar]
  65. Spencer F.A. Ginsberg J.S. Chong A. Alter D.A. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J. Thromb. Haemost. 2008 6 9 1507 1513 10.1111/j.1538‑7836.2008.03062.x 18624983
    [Google Scholar]
  66. Mäkivaara L.A. Ahti T.M. Luukkaala T. Hakama M. Laurikka J.O. Persons with varicose veins have a high subsequent incidence of arterial disease: a population-based study in Tampere, Finland. Angiology 2007 58 6 704 709 10.1177/0003319707299202 18216380
    [Google Scholar]
  67. Matic M. Matic A. Djuran V. Gajinov Z. Prcic S. Golusin Z. Frequency of Peripheral Arterial Disease in Patients With Chronic Venous Insufficiency. Iran. Red Crescent Med. J. 2016 18 1 e20781 10.5812/ircmj.20781 26889387
    [Google Scholar]
  68. Eliasson Å. Bergqvist D. Björck M. Acosta S. Sternby N.H. Ögren M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23 796 consecutive autopsies. J. Thromb. Haemost. 2006 4 9 1897 1902 10.1111/j.1538‑7836.2006.02152.x 16881933
    [Google Scholar]
  69. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994 308 6923 235 246 10.1136/bmj.308.6923.235 8054013
    [Google Scholar]
  70. Simes J. Becattini C. Agnelli G. Eikelboom J.W. Kirby A.C. Mister R. Prandoni P. Brighton T.A. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014 130 13 1062 1071 10.1161/CIRCULATIONAHA.114.008828 25156992
    [Google Scholar]
  71. Becattini C. Agnelli G. Schenone A. Eichinger S. Bucherini E. Silingardi M. Bianchi M. Moia M. Ageno W. Vandelli M.R. Grandone E. Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med. 2012 366 21 1959 1967 10.1056/NEJMoa1114238 22621626
    [Google Scholar]
  72. Cavallari I. Morrow D.A. Creager M.A. Olin J. Bhatt D.L. Steg P.G. Storey R.F. Cohen M. Scirica B.S. Piazza G. Goodrich E.L. Braunwald E. Sabatine M.S. Bonaca M.P. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation 2018 137 7 684 692 10.1161/CIRCULATIONAHA.117.031062 29084737
    [Google Scholar]
  73. Eikelboom J.W. Connolly S.J. Bosch J. Dagenais G.R. Hart R.G. Shestakovska O. Diaz R. Alings M. Lonn E.M. Anand S.S. Widimsky P. Hori M. Avezum A. Piegas L.S. Branch K.R.H. Probstfield J. Bhatt D.L. Zhu J. Liang Y. Maggioni A.P. Lopez-Jaramillo P. O’Donnell M. Kakkar A.K. Fox K.A.A. Parkhomenko A.N. Ertl G. Störk S. Keltai M. Ryden L. Pogosova N. Dans A.L. Lanas F. Commerford P.J. Torp-Pedersen C. Guzik T.J. Verhamme P.B. Vinereanu D. Kim J.H. Tonkin A.M. Lewis B.S. Felix C. Yusoff K. Steg P.G. Metsarinne K.P. Cook Bruns N. Misselwitz F. Chen E. Leong D. Yusuf S. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N. Engl. J. Med. 2017 377 14 1319 1330 10.1056/NEJMoa1709118 28844192
    [Google Scholar]
  74. Agarwal V. Phung O.J. Tongbram V. Bhardwaj A. Coleman C.I. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int. J. Clin. Pract. 2010 64 10 1375 1383 10.1111/j.1742‑1241.2010.02439.x 20716146
    [Google Scholar]
  75. Li R. Yuan M. Yu S. Fu W. Yu W. Ling S. Sun J. Chen Y. Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis. Pharmacol. Res. 2021 165 105413 10.1016/j.phrs.2020.105413 33412275
    [Google Scholar]
  76. Wallace A. Albadawi H. Hoang P. Fleck A. Naidu S. Knuttinen G. Oklu R. Statins as a preventative therapy for venous thromboembolism. Cardiovasc. Diagn. Ther. 2017 7 S3 Suppl. 3 S207 S218 10.21037/cdt.2017.09.12 29399524
    [Google Scholar]
/content/journals/cvp/10.2174/0115701611345232250212042958
Loading
The Link between Arterial Atherosclerotic and Venous Thromboembolic Disease
Bentham Science Publishers ; https://doi.org/10.2174/0115701611345232250212042958
/content/journals/cvp/10.2174/0115701611345232250212042958
/content/journals/cvp/10.2174/0115701611345232250212042958
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: antithrombotic drugs ; venous thromboembolism ; inflammation ; Arterial atherosclerotic disease ; risk factors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test